[Form 4] Guardant Health, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 filed for Guardant Health, Inc. (GH) details a routine equity award vesting by director Steve E. Krognes on 06/30/2025. Krognes converted 154 restricted stock units (RSUs)—originally granted on 08/09/2022—into the same number of common shares at a stated price of $0, reflecting a non-cash, in-kind issuance. Following the transaction, he directly owns 17,819 common shares and retains 1,852 unvested RSUs. The RSU grant vests monthly through 06/30/2026, and no shares were sold. The filing signifies ordinary executive compensation activity with no immediate balance-sheet or cash-flow impact on the company.

Insights

Securities Analyst

TL;DR: Small RSU vesting; no market impact.

The 154-share conversion is immaterial relative to Guardant Health’s ~100 million-share float. No open-market purchase or sale occurred, so supply–demand dynamics remain unchanged. Insider holdings edge slightly higher, supporting long-term alignment but offering no insight into near-term fundamentals. I view the disclosure as neutral for investors.

Corporate Governance Expert

TL;DR: Routine equity award, governance neutral.

Monthly-vesting RSUs are typical for director compensation. The attorney-in-fact signature and timely filing meet Section 16 requirements, indicating sound compliance. Because no disposition occurred, there are no governance red flags. Impact on shareholder value is negligible.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Krognes Steve E.

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/30/2025		M		154	A	$0	17,819	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	06/30/2025		M			154	(1)	(2)	Common Stock	154	$0	1,852	D

Explanation of Responses:

1. This represents a restricted stock unit award granted on August 9, 2022 that vested 25% of the shares subject to such award on June 30, 2023. The remaining 75% of the shares subject to such award vests in substantially equal installments on each monthly anniversary of June 30, 2023 during the three-year period thereafter.

2. Not applicable for Restricted Stock Units.

Remarks:

	/s/ John Saia, as attorney-in-fact for Steve Krognes	07/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Guardant Health (GH) report in the latest Form 4?

Director Steve E. Krognes converted 154 RSUs into common stock on 06/30/2025.

How many Guardant Health shares does Steve Krognes now own?

Post-transaction, he directly holds 17,819 common shares plus 1,852 unvested RSUs.

Was any cash exchanged in the 06/30/2025 transaction?

No. The RSU conversion price was $0; it was a non-cash issuance.

Does the Form 4 indicate any share sales by the director?

No shares were sold; the filing records only an acquisition via vesting.

When will the remaining RSUs granted on 08/09/2022 fully vest?

They vest in equal monthly installments through 06/30/2026.